Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 531752 | NSE Symbol : | ISIN : INE703D01023 | Industry : Finance & Investments |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
15-Apr-2025	15-Apr-2025	Preferential Issue	This is to Inform you that at the Meeting of the Board of Directors of the Company held today on Tuesday, 15th April 2025 It has further informed that all final call is called up on 08.04.2025 and so now warrants are fully paid up and converted into equity shares of the Company on the preferential basis and allotted as the pdf attached. The meeting commenced at 03:30 P.M. and concluded at 04:00 P.M. : Please take this on your record. This is for your information Thanking You.
08-Apr-2025	08-Apr-2025	Preferential Issue	Board Meeting Outcome for Outcome Of Board Meeting Held On Today 08.04.2025.
21-Mar-2025	21-Mar-2025	Preferential Issue	We wish to inform that the Board of Directors in their meeting held today, i.e., March 21, 2025, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty-Five Crore Only) equity share warrants to non-promoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty-eight paise) each upon receipt of other 5% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached as Annexure A. The meeting commenced at 04:00 P.M. and concluded at 04:30 P.M. This is for your information.
11-Mar-2025	11-Mar-2025	Preferential Issue	We wish to inform that the Board of Directors in their meeting held today, i.e., March 11, 2025, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty-Five Crore Only) equity share warrants to non-promoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty-eight paise) each upon receipt of other 5% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached as Annexure A. The meeting commenced at 03:30 P.M. and concluded at 04:05 P.M. This is for your information.
07-Mar-2025	07-Mar-2025	Preferential Issue	We wish to inform that the Board of Directors in their meeting held today, Le., March 7, 2025, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty-Five Crore Only) equity share warrants to nonpromoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty-eight paise) each upon receipt of other 5% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9,2015 is attached as Annexure A. The meeting commenced at 03:30 P.M. and concluded at 04:00 P.M. This is for your information. Thanking You.
22-Jan-2025	05-Feb-2025	Quarterly Results	Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2025 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday 5th February 2025 inter alia to consider following business. - 1.) To approve and take on record the Un-Audited Financia l Results of the Company for the quarter ended on 31t December 2024. 2.) To approve and consider the appointment of Mr. Kelash Bunkar as Whole time Director and Chief Financial Officer of the Company. 3.) To consider the resignation of Mr. Niraj Vaghela from designation of Whole time Director and Chief Financial Officer of the Company. 4.)To approve and consider the appointment of Mr. Aman Patel as Director of the Company. 5.) To consider the resignation of Ms. Komal Chauhan from directorship of the Company. 6.) Any other matter with the permission of the board which the Board may think fit. Thanking You. 1.) Considered and approved Un-audited financial results for the quarter and nine months ended on 31st December 2024. 2.) The board has considered and approved the appointment of Mr. Kelash Bunkar as Whole-time Director and Chief Financial Officer of the Company w.e.f 05.02.2025. 3.) The board has considered and accepted the resignation of Mr. Niraj Vaghela from designation of Whole time Director and Chief Financial Officer of the Company w.e. f 05.02.2025 4.) Mr. Aman Patel is appointed as non-executive independent director of the company w .e. f. 05.02.2025 subject to approval of members. 5.) The board has considered and accepted the of Independent Director Ms Komal Chauhan w e.f 05.02.2025. The board meeting commenced at 03:30 PM and concluded at 04:25 PM (As per BSE Announcement Dated on 05/02/2025)
17-Jan-2025	17-Jan-2025	Preferential Issue	We wish to inform that the Board of Directors in their meeting held today, i.e., January 17 2025, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty-Five Crore Only) equity share warrants to non-promoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty-eight paise) each upon receipt of other 40% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached as Annexure A. The meeting commenced at 05:00 P.M. and concluded at 05:30 P.M. This is for your information. Thanking You.
29-Nov-2024	29-Nov-2024	Preferential Issue	We wish to inform that the Board of Directors in their meeting held today, i.e., 29th November 2024, inter-alia, considered and approved the following items: 1. Allotment of 25,00,00,000 (Twenty Five Crore Only) equity share warrants to non-promoters on Preferential Basis at an issue price of Rs. 1.68/- (Rupees one and sixty eight paise) each upon receipt of 25% of the total consideration. The above said allotments have been made in accordance with the terms mentioned in the notice of Postal Ballot dated 13.08.2024 and in compliance with the applicable provisions of the Companies Act, 2013 and SEBI (ICDR) Regulations. Disclosures pursuant to the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is attached as Annexure A. The meeting commenced at 5:30 P.M. and concluded at 06:00 P.M. This is for your information Thanking You.
15-Oct-2024	13-Nov-2024	Quarterly Results	Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve PFA Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of t he SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Wednesday 13th November 2024 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th September, 2024. The meeting commenced at 05.30 P.M. and concluded at 06.00 P.M. Kindly take the same on your record and oblige. Thanking You. (As per BSE Announcement Dated on 13/11/2024)
01-Aug-2024	13-Aug-2024	Preferential Issue	Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve PFA Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 ,inter alia, to consider and approve Pursuant to regulation 29(1)(d) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the meeting of Board of Director of the Company which is going to be held today Friday, August 9 2024 stands postponed due to unavoidable circumstances and rescheduled on 13th August 2024 (As per BSE Announcement Dated on 09/08/2024) PFA (As per BSE Announcement dated on 13/08/2024)
25-Jul-2024	01-Aug-2024	Quarterly Results	Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2024 inter alia to consider and approve 1.) To approve and take on record the Un-Audited Financial Results of the Company for the quarter ended on 30th June 2024. 2.) Any other matter with the permission of the board which the Board may think fit. Please take the above intimation in your records. Thanking You. PFA (As per BSE Announcement Dated on 01/08/2024)
16-May-2024	25-May-2024	Accounts	Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Saturday 25th May 2024 at registered office of the company inter alia to consider following business. 1. Approve and take on record the Audited Standalone Financial Results of the Company for the quarter and year ended on 3pt March 2024. 2. Any other matter which the Board may think fit. Please take the above intimation in your records. Thanking You. Audited Financial Results for the Quarter and Year Ended on 31st March, 2024 Outcome of the Board Meeting held on 25th May 2024. (As Per BSE Announcement Dated on 25.05.2024)
16-Jan-2024	22-Jan-2024	Quarterly Results	Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/01/2024 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Monday January 22 2024 inter alia to approve and take on record the Un-Audited Financial Results of the Company for the quarter ended on 31st December 2023 also transact other business activities. Please take the above intimation in your records. Thanking You. Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company met in their meeting held on today i.e. Monday 22nd January 2024 . 1.) Considered and approved Un-audited financial results for the quarter ended as on 31st December 2023. The meeting commenced at 04.15 P.M. and concluded at 04.45 P.M. Kindly take the same on your record and oblige. Thanking You PFA (As per BSE Announcement Dated on 22/01/2024) PFA (As per BSE Announcement Dated on 13/02/2024)
03-Jan-2024	09-Jan-2024	Change in Directors	Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/01/2024 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday January 92024 inter alia to consider the appointment and Resignation of Director. Please take the above intimation in your records. Thanking You. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that a meeting of the Board of Directors of the Company held today 09th January 2024 inter alia, and consider following businesses. 1. Ms. Chhaya Parmar is appointed as non-executive independent director of the company w e f. 09.01.2024 subject to approval of members. 2. The board has considered and accepted the resignation of Independent Director Ms Manjula Parmar w e.f 09.01.2024. The board meeting started at 12.30 P.M. and concluded at 01.00. P M. Please take the same on your record. (As Per BSE Announcement Dated on 09.01.2024) PFA (As Per BSE Announcement dated on 10.01.2024)
26-Oct-2023	01-Nov-2023	Quarterly Results	Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2023 inter alia to consider and approve Notice pursuant to regulation 29 of SEBI (LODR) Regulation 2015 be and is hereby given that the meeting of the Board of Directors of the Company will be held on Wednesday November 1 2023 inter alia to consider the Un-Audited financial results of the company for quarter and half year ended on September 30 2023 and also transact other business activities. Please take the above intimation in your records. Thanking you.

1 2 3

LOGIN HERE

Biogen Pharmachem Industries Ltd

Board Meeting